VPD-737 for Treatment of Chronic Pruritus
A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus
Sponsor: Vyne Therapeutics Inc.
Listed as NCT01951274, this PHASE2 trial focuses on Chronic Pruritus and remains completed. Sponsored by Vyne Therapeutics Inc., it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Completed PHASE2
-
Jun 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2020 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vyne Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .